A major nuclear physics research institute looking to build a capability in nuclear medicine needed support with its R&D plan. Alacrita was engaged to help craft a new R&D strategy.
Led by an expert in radiopharmaceuticals with 25 years’ experience in nuclear medicine R&D and business development, our radiopharmaceuticals consultants developed an R&D strategy. We visited our client’s facilities and interviewed key members of staff to assess their current capability and infrastructure. We then interviewed several key opinion leaders to develop an up-to-date and clear understanding of the future opportunities in nuclear medicine. We delivered three strategic options for the client to consider, ranging from semi-virtual through to fully integrated, and for each option set out the infrastructure, personnel and investment needed, expected timelines and likely return on investment. We provided specific recommendations with respect to radioisotopes of special interest, unmet needs for new diagnostic tracers and set out a number of therapeutic strategies in major disease indications. To accelerate their entry into the field, we presented a number of promising in-licensing opportunities.Back